The pshHIF-1α3 stealth
nanospheres have been studied if they have the function of arterial targeted drug delivery to provide a new arterial targeted drug delivery method for interventional
therapy of
lung cancer. The study is also aimed at exploring
therapeutic effect of the checked drug delivery on
lung cancer. The tested groups were designed as follows: Group I: blank control group (pulmonary artery perfusion of 0.5 mL
0.9% saline); group II: tail vein injection of pshHIF-1α3 nano-
microsphere; group III: pshHIF-1α3 nano-
microsphere pulmonary artery perfusion group. In vitro experiment assessed the effects of pulmonary artery perfusion of pshHIF-1α3
nanospheres on proliferation, apoptosis and colony forming ability of
lung cancer A549 cells, which were all evaluated by using MTT method, flow cytometry and colony formation experiments, respectively. In vivo experiment
tumor xenotransplantation was used to observe the effect of pulmonary artery perfusion of pshHIF-1α3
nanospheres on treatment of
lung cancer. Both the In vivo pulmonary artery perfusion experiment and In vitro experiments in A549 cells confirmed that the pulmonary artery perfusion of pshHIF-1α3 nano-
microspheres can inhibit the proliferation of
lung cancer tissues and cells, promoting apoptosis and inhibiting migration, leading to enhanced
therapeutic effect of
lung cancer. One of characteristics of nanomaterials is their large surface area, high dispersion, specific adhesion,
tumor-specific affinity and adhesion, thereby prolonging their circulation time in the body. Through aggregation of nanodrug delivery system in
tumor cells, the local concentration of the drug is increased, thereby improving selectivity of chemotherapeutic drugs. The results from this study therefore suggest that pulmonary artery perfusion of pshHIF-1α3 may be used in arterial targeted drug delivery for treatment of
lung cancer, providing a new and efficient targeted drug delivery arterial route for interventional
therapy of
lung cancer.